Transforming promising science into products for patient benefit

Technology Development Fund (TDF) Overview:

The TDF is a seed-stage academic catalyst fund dedicated to translating high-impact academic technologies into the independently-validated, later-stage opportunities sought by industry partners and investors. Technologies funded by TDF range from therapeutics and devices, to diagnostics and vaccines in both pediatric and adult indications.

The TDF cycle will be delayed for 2021. To receive update on the opening of the 2021 cycle, please email For information on previous TDF cycle details and deadlines, see grants.

Additional events and opportunities can be found on our events page.

Our Approach:

Fund promising technologies through two mechanisms: Pilot Grant – up to $50,000 to validate early-stage projects; Development Grant – up to $150,000 to advance validated projects.

Coach clinicians and scientiststhrough a broad network of advisors, to identify and reach key milestones toward product development.

Partner with academic and corporate collaborators, including a network of 45 contract research organizations (CROs), to leverage technical and product development expertise for drugs, medical devices, and software.

Manage projects and partnerships to maintain focus on development goals.

TDF by the Numbers: 2009-2018

  • $8.5M commitment to 74 projects
  • $38M in follow-on funding to Boston Children’s Hospital
  • 14 licenses with commercial partners
  • 11 new companies with $104M in seed funding
  • $10M in licensing revenue